Navigation Links
Generex Touts Pipeline Potential of Antigen Express Subsidiary
Date:2/7/2013

platform.  This technology enhances delivery of key target proteins like HER2 for cancer to a critical immune recognition site enhancing immune recognition. The Company has also developed compounds designed for important non-HER2 cancer associated protein targets using the Ii-Key technology platform. These include the melanoma-associated gp100 target, as well as cervical and head-and-neck cancers associated with Human Papilloma Virus (HPV). These compounds have shown significant activity in animal models that has been described in peer-reviewed publications.

In addition to cancer protein targets, the Company has clinically tested Ii-Key-based proteins designed to protect against the potentially pandemic influenza strains H5N1 (avian flu) and H1N1 (swine flu). The advantage here is that the Antigen vaccine technology is entirely synthetic, making it simple to manufacture. In the event of a potentially pandemic influenza virus, there is clearly a need for this type of flexible vaccine technology that can be brought into production rapidly.

The distinguishing feature of Antigen Express technology (Ii-Key) is the ability to activate critical components of the immune system (CD4+ T helper cells) in a robust and specific manner. Currently this is a unique technology platform that directs proteins to a critical immune component to be able to create specific immune stimulation. This Ii-Key technology is proprietary to Antigen Express. Consequently, the Company is in a good position to license the technology for combination with multiple different target proteins to create novel vaccine applications that may be of interest to other researchers and companies.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavit
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
10. Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
11. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 RadiologyAuction will have their first ... and product demonstrations at the end of the auction ... as Kodak and Fuji Cr,s, Agfa and Sony, printers ... first event. Various imaging equipment will be available at ... After years of buying and selling imaging equipment, ...
(Date:5/4/2015)... 2015 Rogne Bioscience, a privately-held biotechnology company ... preclinical and mechanism of action data will be presented ... Dermatology (SID) Annual Meeting being held May 6-9, 2015 ... . Logo - http://photos.prnewswire.com/prnh/20150501/213318LOGO ... a novel, low MW (<1700 daltons) peptide as a ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... SINGAPORE , UPPSALA, Sweden and CANTON, Mass. , ... that the US Food and Drug Administration (FDA) has given the ... Mesh, for use in reinforcement of soft tissues where weakness exists. ... synthetic matrix, knitted from two different resorbable fibers that degrade at ...
... SAN FRANCISCO, Calif. , Feb. 5 Poniard Pharmaceuticals, Inc. ... today announced that Ronald Martell , chief executive officer, will provide ... on Tuesday, February 9, 2010 at 1:00 p.m. Eastern ... . , A live audio webcast of the corporate overview will be ...
Cached Medicine Technology:Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 2Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 3Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference 2
(Date:5/4/2015)... 05, 2015 The National ... Irene Taylor , Volunteer Executive Director of National ... inductee into its VIP Woman of the Year ... for leadership in business. NAPW is the nation's ... more than 700,000 members and over 200 Local ...
(Date:5/4/2015)... The National Association of Professional Women ... a 2015-2016 inductee into the NAPW VIP Woman of ... distinction for leadership in healthcare. NAPW is the nation's ... than 700,000 members and over 200 operating Local Chapters. ... group of professional women,” says NAPW President Star Jones. ...
(Date:5/4/2015)... (PRWEB) May 05, 2015 The ... Shirley Weis as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in healthcare. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor,” says NAPW President Star Jones. ...
(Date:5/4/2015)... IOWA (PRWEB) May 04, 2015 The ... appointed Gregs G. Thomopulos, P.E., Chairman of Stanley ... (ISI) board of directors for a three-year term. ... Association (APWA) and the American Society of Civil Engineers ... a sustainability rating system for civil infrastructure called Envision. ...
(Date:5/4/2015)... 04, 2015 HHT is a rare ... While it can have seemingly mild symptoms like ... events. Hereditary Hemorrhagic Telangiectasia (HHT) is a hereditary ... lack normal capillary connections between an artery and a ... severe nosebleeds, but may also be present in the ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Irene Taylor into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Jennifer Yates Doherty, Owner of Palmetto Rehabilitation Services, LLC, into its 2015 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 3Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3
... May 20 (ZealousPR) Award-winning Vanity,Fair writer and hospice ... tri-weekly "advice column on dying well,", http://www.TheCheckoutLine.org -- ... who care about them, today. Every Monday, Wednesday and,Friday, ... questions,and offering advice for anyone needing help on the ...
... of developing asthma and allergy because of different conditions ... from the Isle of Wight in the United Kingdom, ... 2008 International Conference in Toronto on Wednesday, May 21., ... asthma and allergy in first-born children is the result ...
... Allows Patients the Ability to Share their Prescription ... Longs Drug,Stores Corporation (NYSE: LDG ) announced ... a platform for sharing of information between,patients and ... of the first,pharmacies to provide their customers with ...
... CHICAGO (May 19, 2008) New research published in ... long-term survival and liver rejection rates are equivalent for ... other races. The study also suggests that although other ... influence long-term survival, race does not. , ...
... ... Leadership, CHICAGO, May 19 Ventas, Inc. (NYSE: VTR ... declared,a regular quarterly dividend of $0.5125 per share, payable in cash ... The dividend is the,second quarterly installment of the Company,s 2008 annual ...
... procedure performed by Dr. Robert S. Bray, Jr. of ... D.I.S.C. Spine ... Roach is living,her dream after successfully qualifying for the 2008 ... one of the country,s preeminent,neurological spinal surgeons specializing in micro ...
Cached Medicine News:Health News:Award Winning Vanity Fair Contributing Editor Judy Bachrach Launches 'TheCheckoutLine.org - An Advice Column on Dying Well' 2Health News:First-born babies' higher asthma and allergy rates due to pregnancy conditions 2Health News:Longs Drugs Partners With Google on the Launch of Google Health 2Health News:Study concludes no racial disparities in long-term outcomes in recipients of liver transplants 2Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 4Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 5Health News:Successful Back Surgery Propels Olympic Weightlifting Hopeful Melanie Roach to Realize Her Dreams Of Participating in the 2008 Beijing Olympics 2
Straight heavy shafts with delicate 7 mm tying platform. Sharp pointed tips for removing fine sutures. Wide serrated handle with polished finish. Overall length 4.1 inches....
Angled 45 degree shafts with 10.5 mm tying and 1 mm of tip crisscross serrated. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.2 inches....
Curved, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Titanium. Straight shafts with 6.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.4 inches....
Medicine Products: